Genetic studies in idiopathic short stature

Current Opinion in Pediatrics

Volumn 12, Issue 4, 2000, Pages 400-404

  Attie, Kenneth M ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; SEX HORMONE; SOMATOMEDIN C;

CHILD; DYSCHONDROSTEOSIS; GENE MUTATION; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; HUMAN; PRIORITY JOURNAL; REVIEW; SHORT STATURE; TURNER SYNDROME;

BODY HEIGHT; FEMALE; GONADOTROPIN-RELEASING HORMONE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; MALE; MUTATION; PHENOTYPE; RECEPTORS, GROWTH FACTOR; TURNER SYNDROME; X CHROMOSOME; Y CHROMOSOME;

EID: 0033910371     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200008000-00021     Document Type: Review

References (34)

1. 1 Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J: Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994, 15:369-390.
2. 2 De Vos AM, Ultsch M, Kossiakoff AA: Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992, 255:306-312.
3. 3 Leung DW, Spencer SA, Cachianes G, et al.: Growth hormone receptor and serum binding protein: Purification, cloning and expression. Nature 1987, 330:537-543.
4. 4 Woods KA, Clark AJ, Amselem S, et al.: Relationship between phenotype and genotype in growth hormone insensitivity syndrome. Acta Paediatr Suppl 1999, 88:158-162. This review of patients with GH insensitivity is valuable for demonstrating the molecular, clinical, and biochemical variability and the limits to which the genotype predicts phenotype. The conclusion that the phenotype of Laron syndrome probably involves the contribution of genes other than that for the GH receptor is intriguing.
5. 5 Woods KA, Fraser NC, Postel-Vinay M-C, et al.: A homozygous splice site mutation affecting the intracellular domain of the growth hormone receptor resulting in Laron syndrome with elevated growth hormone binding protein. J Clin Endocrinol Metab 1996, 81:1686-1690.
6. 6 Silbergeld A, Dastot F, Klinger B, et al.: Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree. J Pediatr Endocrinol Metab 1997, 10:265-274.
7. 7 Ayling RM, Ross R, Towner P, et al.: A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet 1997, 16:13-14.
8. 8 Iida K, Takahashi Y, Kaji H, et al.: Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab 1998, 83:531-537.
9. 9 Goddard AD, Dowd P, Chernausek S, et al.: Partial growth-hormone insensitivity: the role of growth-hormone receptor mutations in idiopathic short stature. J Pediatr 1997, 131 (suppl):51-55.
10. 10 Iida K, Takahashi Y, Kaji H, et al.: The C422F mutation of the growth hormone receptor gene is not responsible for short stature. J Clin Endocrinol Metab 1999, 84:4214-4219.
11. 11 Savage MO, Woods KA, Johnston LB, et al.: Defects of the growth hormone receptor and their clinical implications. Growth Horm IGF Res 1999, 9(SupplA):57-61.
12. 12 Clayton PE, Freeth JS, Whatmore AJ, et al.: Signal transduction defects in growth hormone insensitivity. Acta Paediatr Suppl 1999, 88:174-178.
13. 13 Attie KM, Julius JR, Stoppani C, et al.: National Cooperative Growth Study: substudy VI: the clinical utility of growth-hormone-binding protein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3 measurements. J Pediatr 1997, 131(suppl):56-60.
14. 14 Carlsson LMS, Attie KM, Compton PG, et al.: Reduced concentration of serum growth hormone-binding protein in children with idiopathic short stature. J Clin Endocrinol Metab 1994, 78:1325-1330.
15. 15 Attie KM, Carlsson LMS, Rundle AC, et al.: Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. J Pediatr 1995, 127:244-250.
16. 16 Goddard AD, Covello R, Luoh SM, et al.: Mutations of the growth hormone receptor in children with idiopathic short stature. N Engl J Med 1995, 333:1093-1098.
17. 17 Hintz RL, Attie KM, Baptista J, et al., for the Genentech Collaborative Group: Effect of growth hormone treatment on adult height of children with idiopathic short stature. N Engl J Med 1999, 340:502-507. This article adds the perspective of the effects of long term GH treatment in patients with idiopathic short stature. It is useful to consider these data in the context of the genetic analysis done in the same patients [9].
18. 18 Sanchez JE, Perera E, Baumbach L, et al.: Growth hormone receptor mutations in children with idiopathic short stature. J Clin Endocrinol Metab 1998, 83:4079-4083.
19. 19 Clayton PE, Freeth JS, Norman MR: Congenital growth hormone insensitivity syndromes and their relevance to idiopathic short stature. Clin Endocrinol 1999, 50:275-283. This review article is a thoughtful summary of the spectrum of GH the insensitivity. It describes how the location of the mutations affect GHBP levels and discusses both obligate heterozygotes in the families of patients with Laron syndrome and issues of familial short stature and partial GH insensitivity.
20. 20 Ellison JW, Wardak Z, Young MF, et al.: PHOG, a candidate gene for involvement in the short stature of Turner syndrome. Hum Mol Genet 1997, 6:1341-1347.
21. 21 Rao E, Weiss B, Fukami M, et al.: Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner. Nat Genet 1997, 16:54-63.
22. 22 Belin V, Cusin V, Viot G, et al.: SHOX mutations in dyschondrosteosis (Leri-Weill syndrome). Nat Genet 1998, 19:67-69.
23. 23 Shears DJ, Vassal HJ, Goodman FR, el al.: Mutation and deletion of the pseudoautosomal gene SHOX cause Leri-Weill dyschondrosteosis. Nat Genet 1998, 19:70-73.
24. 24 Cormier-Daire V, Belin V, Cusin V, et al.: SHOX gene mutations and deletions in dyschondrosteosis or Leri-Weill syndrome. Acta Paediatr Suppl 1999, 88:55-59.
25. 25 Kosho T, Muroya K, Nagai T, et al.: Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX: implications for the development of Turner syndrome. J Clin Endocrinol Metab 1999, 84:4613-4621. This study presents a thorough analysis of 14 Japanese patients with chromosomal defects affecting the SHOX gene. In addition to detailed deletion maps of the pseudoautosomal region for each patient, phenotype is described with special attention to skeletal features and growth, indicating which features may be attributed to the SHOX gene.
26. 26 de Vries BB, Eussen BH, van Diggelen OP, et al.: Submicroscopic Xpter deletion in a boy with growth and mental retardation caused by a familial t(X;14). Am J Med Genet 1999, 87:189-194.
27. 27 Ogata T: SHOX: pseudoautosomal homeobox containing gene for short stature and dyschondrosteosis. Growth Horm IGF Res 1999, 9(Suppl B):53-57.
28. 28 Binder G, Schwarze CP, Ranke MB: Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone. J Clin Endocrinol Metab 2000, 85:245-249. This study illustrates the proper approach to analyzing the prevalence of a mutation in a given population. Similar to earlier studies of the GH receptor, this study of the SHOX gene in a group of ISS patients included molecular screening with PCR amplification and single strand conformation analysis, as well as paternity analysis when appropriate. In addition, the GH treatment of two siblings with a SHOX defect is discussed.
29. 29 Shanske A, Ellison J, Vuguin P, et al.: Deletion of the pseudoautosomal region in a male with a unique Y;13 translocation and short stature. Am J Med Genet 1999, 82:34-39.
30. 30 Parks JS, Brown MR, Hurley DL, et al.: Heritable disorders of pituitary development. J Clin Endocrinol Metab 1999, 84:4362-4370.
31. 31 Takahashi Y, Kaji H, Okimura Y, et al.: Short stature caused by a mutant growth hormone with an antagonistic effect. Endocrinol J 1996, 43(suppl):27-32.
32. 32 Baumann G: Mutations in the growth hormone releasing hormone receptor: a new form of dwarfism in humans. Growth Horm IGF Res 1999, 9(Suppl B):24-29.
33. 33 Woods KA, Camacho-Hubner C, Savage MO, et al.: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996, 335:1363-1367.
34. 34 Camacho-Hubner C, Woods KA, Miraki-Moud F, et al.: Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion. J Clin Endocrinol Metab 1999, 84:1611-1616. Although only one patient with partial IGF-I gene deletion has been described, much can be learned from this patient. This article details the hormonal profile of the patient before and after recombinant IGF-I therapy, showing interesting effects on GH, IGF binding proteins, insulin, and growth.